Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for serious metabolic diseases with significant unmet need. Its lead program centers on efruxifermin, an engineered FGF21 analog being advanced for metabolic dysfunction-associated steatohepatitis, a progressive liver disease linked to metabolic dysregulation and limited current treatment options. The company’s strategy targets restoration of whole‑body metabolic balance to address liver inflammation, fibrosis, and broader cardiometabolic risk factors inherent to the condition. Akero has reported Phase 2b readouts demonstrating statistically significant histologic improvements in pre-cirrhotic disease and signals in compensated cirrhosis, and has initiated a Phase 3 program evaluating efficacy and real-world safety in MASH populations. By concentrating on a potential backbone therapy for a high-prevalence, high-burden indication, Akero occupies a prominent role in the biopharmaceutical effort to bring disease-modifying treatments to metabolic liver disease. The company’s progress and clinical catalysts are closely watched by healthcare stakeholders given the scale of MASH and its impact across endocrine, hepatology, and cardiometabolic care pathways.